Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 4.50 (-2.60%)
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling...

ABUS : 4.50 (-2.60%)
Arbutus Biopharma Showcases Data at Liver Meeting 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Arbutus Biopharma...

ABUS : 4.50 (-2.60%)
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data  – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as...

ABUS : 4.50 (-2.60%)
Arbutus: Q2 Earnings Snapshot

Arbutus: Q2 Earnings Snapshot

ABUS : 4.50 (-2.60%)
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation...

ABUS : 4.50 (-2.60%)
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

ABUS : 4.50 (-2.60%)
Arbutus: Q1 Earnings Snapshot

Arbutus: Q1 Earnings Snapshot

ABUS : 4.50 (-2.60%)
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

ABUS : 4.50 (-2.60%)
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

ABUS : 4.50 (-2.60%)

Barchart Exclusives

2 High-Yield Dividend Aristocrats to Consider in 2026
These Dividend Aristocrats stand out due to their relatively high yields. Moreover, both these companies have the potential for continued dividend growth in the years ahead. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar